Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.7K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.7K
Chemical Synapses01:26

Chemical Synapses

11.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
11.1K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

859
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
859

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the International Weed Genomics Consortium genome annotation pipeline through reannotation of the model species Arabidopsis thaliana.

The plant genome·2026
Same author

Range of detection and naturalistic search performance for spotted lanternfly (<i>Lycorma delicatula</i>) egg masses.

PeerJ·2026
Same author

Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.

Diabetes, obesity & metabolism·2026
Same author

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study.

Ophthalmology·2026
Same author

VO: The Vaccine Ontology.

Scientific data·2026
Same author

Tumor Necrosis Factor Inhibitor Treatment and Persistence Patterns in the Peripregnancy Period in Patients With Inflammatory Autoimmune Diseases.

ACR open rheumatology·2026

Related Experiment Video

Updated: Jan 9, 2026

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

25.4K

Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis.

Melanie H Jacobson1, Rupa Makadia1, Ashley E L Anderson2

  • 1Johnson & Johnson, Horsham, Pennsylvania, USA.

Muscle & Nerve
|December 3, 2025
PubMed
Summary

Pregnancy in myasthenia gravis (MG) is linked to increased risks of preeclampsia, Cesarean section, preterm birth, and infants small for gestational age. Many MG patients remain untreated during pregnancy, highlighting a potential gap in care.

Keywords:
burden of diseasemyasthenia gravisperinatal periodpregnancytreatment patterns

More Related Videos

Home-Based Monitor for Gait and Activity Analysis
07:24

Home-Based Monitor for Gait and Activity Analysis

Published on: August 8, 2019

7.2K
Muscle Velocity Recovery Cycles to Examine Muscle Membrane Properties
08:27

Muscle Velocity Recovery Cycles to Examine Muscle Membrane Properties

Published on: February 19, 2020

14.7K

Related Experiment Videos

Last Updated: Jan 9, 2026

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

25.4K
Home-Based Monitor for Gait and Activity Analysis
07:24

Home-Based Monitor for Gait and Activity Analysis

Published on: August 8, 2019

7.2K
Muscle Velocity Recovery Cycles to Examine Muscle Membrane Properties
08:27

Muscle Velocity Recovery Cycles to Examine Muscle Membrane Properties

Published on: February 19, 2020

14.7K

Area of Science:

  • Neurology
  • Obstetrics
  • Perinatal Health

Background:

  • Myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions.
  • Limited data exists on pregnancy outcomes and treatment patterns in MG patients due to small study sizes.
  • Understanding these outcomes is crucial for optimizing maternal and infant care.

Purpose of the Study:

  • To estimate the prevalence of key perinatal and infant outcomes in pregnancies complicated by MG.
  • To characterize the treatment patterns for MG throughout the perinatal period.
  • To identify potential areas for improved management strategies in pregnant MG patients.

Main Methods:

  • Retrospective cohort study utilizing large US health insurance claims databases (Merative MarketScan CCAE).
  • Identification of pregnancies in females aged 18-49 years, linking maternal and infant records.
  • Definition of MG based on inpatient or outpatient diagnosis codes; calculation of outcome prevalence and summary of treatment classes.

Main Results:

  • MG pregnancies showed higher rates of preeclampsia (10.7% vs 7.1%), Cesarean section (42.9% vs 36.7%), preterm birth (18.0% vs 9.9%), and small for gestational age (4.3% vs 1.7%).
  • A significant proportion of MG patients received no treatment in the 6 months preconception (54.3%), during pregnancy (61.2%), and postpartum (57.8%).
  • Among treated patients, new initiation of acetylcholinesterase inhibitors (21.8%) or corticosteroids (33.1%) during pregnancy was observed.

Conclusions:

  • Myasthenia gravis is associated with an increased prevalence of adverse perinatal and infant outcomes.
  • Under-treatment of MG during the perinatal period is common, suggesting a need for better management protocols.
  • Treatment patterns varied, indicating a potential need for more consistent and timely interventions for pregnant individuals with MG.